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In the long-term, ageing populations may demand more
blood transfusions, but the blood supply could be lim-
ited by difficulties in attracting and retaining a propor-
tionately smaller and decreasing pool of younger donors.
[1,2]. One approach to increase the blood supply, espe-
cially for groups for whom supply tends to be more lim-
ited (for example, people who have O negative and B
negative blood types), is to collect blood more frequently
from existing donors. If more donations could be safely
collected in this manner at marginal cost, then it would
be of considerable benefit to blood services.
The principal risk of more frequent donation is, how-
ever, iron deficiency and a fall in haemoglobin levels [3].
Each blood donation removes about 250 mg of iron
from the body. There is considerable individual variation
in iron stores, dietary intake, and efficiency of absorp-
tion. If iron is not fully replaced, then donors’ iron stores
become progressively depleted, leading to iron deficiency
or the development of frank iron-deficiency anaemia.
Iron deficiency or anaemia may result in adverse health
consequences for donors and their temporary rejection
from giving further donations or ‘deferral’, due to failure
to meet the haemoglobin threshold required for donation.
This threshold, together with limits for donation intervals,
has been set to minimise iron deficiency in repeat blood
donors [4].
In the absence of data from reliable randomised trials
to inform policies on inter-donation intervals, the Coun-
cil of Europe has provided directives for blood collection
that have been open to different national interpretations
[5] (Table 1). NHS Blood and Transplant (NHSBT), the
sole blood provider to the National Health Service (NHS)Table 1 Whole blood inter-donation intervals across
European blood services (weeks)
Men Women
England 12 16
Austria 8 10
Finland 8 12
France 8 12
Germany 8 12
Ireland 10 10
Estonia 10 12
Netherlands 10 16
Denmark 12 12
Flanders 12 12
Wales 12 16
Slovenia 12 16
Spain 12 16
Scotland 16 16in England, currently allows men to donate up to once
every 12 weeks and women to donate up to once every
16 weeks. In contrast, some other European countries
allow donations as frequently as every 8 weeks for men
and every 10 weeks for women.
As part of their duty of care, blood services screen do-
nors at each visit for haemoglobin levels. Across Europe,
minimum thresholds of 13.5 g/dL for men and 12.5 g/dL
for women must be met for donation eligibility [6]. In
Canada and in the USA, the thresholds are 12.5 g/dL for
both men and women [5,7]. In England, about 3% of do-
nors overall are not eligible to donate because of failure
to meet the haemoglobin threshold at screening (unpub-
lished data, NHSBT). Such deferral may demotivate indi-
viduals to donate in the future and directly or indirectly
increase the cost of collecting blood [8,9]. Furthermore,
some donors may not attend scheduled donation ap-
pointments or may self-defer owing to symptoms, which
could be due, at least in part, to iron deficiency or an-
aemia. Therefore, the challenge faced by blood services
is to decrease the incidence of deferrals for low haemo-
globin whilst increasing blood supplies to meet projec-
tions of increasing demand.
We have designed the INTERVAL trial, which is a paral-
lel group, pragmatic randomised trial. INTERVAL has en-
rolled about 50,000 male and female donors at the 25 static
donor centres of NHSBT located throughout England. The
trial’s key anticipated contribution will be to determine
optimum inter-donation intervals that maximise blood sup-
ply and maintain well-being of donors. A subsidiary aim of
the INTERVAL trial is to explore suggestions that donation
intervals could be tailored to donors’ capacity to donate
blood safely. For example, it may be that some donors have
a decreased capacity for frequent donation (for example,
very lean people and/or women of childbearing age who
may be predisposed to anaemia), whereas other donors
may be able to donate more frequently (for example, men,
heavier donors, those who carry genes predisposing to
them to higher iron stores) [10-12].
We confirm that recruitment into the trial was on-
going at the time this manuscript was submitted for
publication.
Methods/Design
Pilot work preceding this trial
Prior to the initiation of INTERVAL, we conducted the
Cambridge CardioResource study [13], a study of 2,500
blood donors from the East Anglia region of the UK in
order to demonstrate the feasibility of embedding re-
search protocols within NHSBT’s routine service setting.
This study showed that it is possible to recruit and con-
sent donors and collect research samples at NHSBT dona-
tion sessions, with 99% of samples being successfully
retrieved. It also demonstrated that donors could complete
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The findings of this pilot study have informed the design
of INTERVAL.Objectives
The dual objectives of INTERVAL are (1) to determine
the optimum intervals between donations for men and
women that maximise blood supply, maintain well-being
of donors, and avoid unacceptably increasing risk of iron
deficiency/anaemia and its potential complications, and
(2) to explore tailoring of blood donation intervals to
donors by their demographic, haematological, genetic
and/or lifestyle characteristics.Hypothesis
We will test the hypothesis that more frequent blood do-
nation than is currently customary in England will in-
crease the total number of blood units collected over
2 years without adversely affecting the health or well-
being of blood donors.Design
INTERVAL is an open, randomised, multisite trial in-
volving the recruitment of about 50,000 male and fe-
male donors from all 25 static donor centres of NHSBT
throughout England. Men have been randomly assigned
to standard 12-week versus 10-week versus 8-week
inter-donation intervals; and women to standard 16-week
versus 14-week versus 12-week intervals (Figure 1). To ex-
plore the potential value of tailoring donation intervals to
possibly relevant subgroups, we have pre-specified analysis
of (a) men and women, (b) carriers of informative variants
in the human haemochromatosis (HFE) gene, (c) pre- and
post-menopausal women, (d) people with body mass
index (BMI) <22, (e) new blood donors, and (f) subgroups
based on baseline measures of iron status (for example,
serum ferritin).Figure 1 Overall design for the INTERVAL trial.Setting and participants
NHSBT collects whole blood from donors attending ei-
ther static donor centres or temporary ‘mobile’ donation
sessions set up at community venues such as village
halls. Recruitment in INTERVAL has been restricted to
donors attending the static donor centres (which are
open daily during the working week), principally be-
cause ‘mobile’ sessions do not typically visit locations
often enough to accommodate donors who would be
allocated to the more frequent intervals being evalu-
ated in INTERVAL. The static donor centres of NHSBT
are located in Birmingham, Bradford, Brentwood, Bristol,
Cambridge, Edgware, Gloucester, Lancaster, Leeds (2 sites)
Leicester, Liverpool, Luton, Manchester (2 sites), Newcastle,
Nottingham, Oxford, Plymouth, Poole, Sheffield, South-
ampton, Stoke on Trent, Tooting (South London), and
West End London. To facilitate the provision of adequate
training support during each site’s first week of participant
recruitment, we commenced recruitment in one new
centre per week. At each centre, designated trained
members of staff adopted the roles of clinical and/or
operational experts to supervise the work of the trial.
The overall approach used in INTERVAL has been to
embed research activity within the existing operational
framework of NHSBT. To support additional functions
required in the trial, we have established an academic
trial coordinating centre at the Department of Public
Health and Primary Care, University of Cambridge. In
addition to supporting the trial’s core scientific activities,
the coordinating centre provides a helpdesk to respond
to queries from participants about the trial, and main-
tains a study website [15]. The academic coordinating
centre has worked closely with the INTERVAL study ad-
ministration team (ISAT) based within NHSBT. For ex-
ample, ISAT has supported the trial to enable participants
to make appointments to give blood at intervals that are
more frequent than current NHSBT practice (which is not
possible through NHSBT’s routine appointment system).
To enhance adherence of trial participants to their
Table 2 Categories for minimisation variables
Men Women
Age <50 years ≥50 years <50 years ≥50 years
Weight <70 kg ≥70 kg <60 kg ≥60 kg
Donor status New Repeat New Repeat
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tensive and systematic efforts than used in routine
NHSBT practice to remind participants about their
blood donation appointments, including a systematic
three-step telephone and email reminder process.
Participant recruitment
Postal invitations to take part in the trial, which included
a copy of the trial information leaflet, have been sent by
NHSBT alongside routine invitations to give blood. Dur-
ing the first 6 months of the trial (June 2012 to January
2013), invitations were sent only to those donors who
were registered at a static donor centre (approximately
147,000 invitations in total). Between January and Octo-
ber 2013, three additional recruitment strategies were
implemented, which included invitations to groups of
‘mobile’ session donors who might be willing to attend a
static centre in order to join the trial. These invitations were
to donors who (1) had previously indicated a willingness to
give platelets at a static centre (approximately 23,000 invita-
tions), (2) gave blood at a ‘mobile’ session within 10 miles of
a static centre (approximately 200,000 invitations), and (3)
lived within 30 miles (but typically within 20 miles) of a
static centre (approximately 189,000 invitations).
Donors received invitations to join the trial at their
next scheduled appointment. At that visit, they were
asked by the donor centre reception staff whether they
had received an invitation for the trial and if they wanted
to join. Donors who had not yet received or read any in-
formation about the trial but who wanted to join were
given the opportunity to read the information leaflet in
the waiting area before donating. If there was insufficient
time to do this, or the donor wanted more time to think
about joining, then a trial information pack was given to
the donor to read and consider before their next dona-
tion. Donors who had read the information and were
willing to take part were asked to confirm their email
and telephone contact details.
Inclusion and exclusion criteria
Participants eligible to take part in the trial are aged
18 years or older, fulfil all normal criteria for blood do-
nation [16], and are willing to be randomised to any of
the trial’s intervention groups. In addition, they must be
willing to donate at one of the static NHSBT donation
centres for the duration of the trial. Study-specific cri-
teria for exclusion from the trial are lack of internet ac-
cess and/or unwillingness to provide an email address
for trial correspondence, since the trial mainly collects
data via remote and web-based methods.
Donor screening and obtaining informed consent
At the donor centres, donors underwent routine screening
for donation eligibility, including haemoglobin measurementvia a copper sulphate test, followed by a Hemocue™ test
for those who failed the copper sulphate test. If the
donor was not eligible to make a donation on that day,
for any reason, then he/she could not join the trial on that
occasion. Donors who were eligible to take part in the trial
were asked if they had any further questions, which were
answered either directly (aided by ‘frequently asked ques-
tions’ material provided by the research team) or for-
warded to the trial ‘champion’ at the donor centre or to
the trial helpline. At this point, donors were asked to
complete and sign both copies of the consent form, which
were checked for completion of all relevant sections and
for the donor’s signature on both copies. On the ‘trial
copy’ of the consent form, the carer affirmed by signature
that he/she had witnessed its completion and retained this
copy while providing the ‘donor copy’ to the participant.
For donors who were not subsequently eligible or willing
to take part, consent forms were crossed through and then
destroyed.
Randomisation, concealment of allocation, and blinding
Randomisation to three sex-specific intervention groups
in the ratio 1:1:1 was undertaken at the academic trial
coordinating centre using individual-level randomisation
achieved by means of a computer programme built into
the trial database. This programme includes a minimisa-
tion algorithm to ensure that key prognostic characteris-
tics are balanced across the trial arms at baseline (for
example, new/repeat donor status, weight and age, as
shown in Table 2). Randomisation was stratified by do-
nation centre and gender. By the nature of the trial, par-
ticipants have not been blinded to the intervention
group to which they have been allocated.
Baseline data collection
On the day following enrolment into the study, NHSBT
confidentially retrieved data on participants from donor
records, including donor number, donation number, dona-
tion date, email and mobile contact details, sex, month and
year of birth, NHS number and previous donation and de-
ferral history in the past 5 years. Using secure systems,
these data were transferred to the academic coordinating
centre to facilitate contact of participants, implementation
of trial protocols, tracking of participants’ appointments
and attendances throughout the trial. A few days after join-
ing the trial, participants received two emails: one contain-
ing a uniform resource locator (URL) link and requesting
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other containing a password to access the online question-
naire. Participants’ trial IDs were embedded within the
URL link using a custom tag to anonymously track com-
pletion of the questionnaire. Participants were requested to
complete the questionnaire within 7 days and received two
email reminders and a phone call between days 7 and 14 if
they did not respond. The baseline questionnaire has been
designed to take approximately 15 minutes to complete
and includes the following:
1. Compulsory questions including month and year of
birth, sex, height, and weight. This information was
used to verify that the questionnaire had been
completed by the individual to whom it was sent,
and also for minimisation algorithm described above.
2. Quality of life questions, using the Short Form
Health Survey (SF-36v2) questionnaire. The SF-36v2
is a generic measure of health status that has been
reported to differentiate well between health benefits
produced by a range of treatments irrespective of
age, disease condition, or treatment group [17-20]. It
is composed of 36 questions and produces an eight-scale
profile of functional health and well-being, as well as
two psychometrically-based summary measures (that is a
physical component score (PCS) and mental component
score) and a preference-based health utility index.
3. Previous history of iron deficiency, which may relate
to susceptibility to iron deficiency.
4. Brief lifestyle information including, diet
(particularly related to iron intake and absorption),
alcohol intake, smoking and physical activity.
Only participants who returned the baseline question-
naire were eligible for randomisation. After randomisa-
tion, participants were advised of their new inter-donation
interval by email and were also informed that appoint-
ments should be made through NHSBT’s ISAT team. The
ISAT team was responsible for making this first appoint-
ment to coincide with the participant’s allocated donation
frequency. For subsequent appointments during the trial,
donors are given the option, and are encouraged, to make
all appointments at their selected donor centre on the oc-
casion of future donation visits.
Once randomised, donors’ participation in the trial
was flagged on their donor record together with their al-
located donation frequency. This flag is critical to (1)
NHSBT donor centre staff, since it is essential for the
booking of future appointments at the correct interval;
(2) the academic coordinating centre’s helpdesk and the
ISAT team, since the flag helps to identify donors’ status
on the trial and resolve any queries; and (3) data man-
agement processes, such as retrieving data on donors at
regular time-points from NHSBT’s donor database andsecurely transferring this information to the trial coord-
inating centre for the purposes of monitoring appoint-
ment bookings and attendance, deferrals, adverse events
of donation, positive microbiology results and deaths.
Blood sample collection, processing, and analysis
At the baseline donation visit at which the participant’s
eligibility was assessed and consent obtained, a research
sample was taken from the satellite pouch that forms
part of the routine blood collection unit (that is, a separ-
ate venipuncture is not required). The research sample
was collected in three tubes: 3 ml EDTA, 6 ml EDTA
and 6 ml serum, which were each inverted three times
before placing in rigid boxes for transport to the three
NHSBT sample holding sites at Manchester, Colindale
(London) and Bristol. Samples were couriered from the
holding sites to the central study laboratory (UK Biocentre,
Stockport, UK) for processing in the morning following
collection. The large majority of samples (97%) were proc-
essed within 24 hours. Samples were kept at ambient
temperature from the point of collection until comple-
tion of processing. Fluctuations in temperature were
monitored at various sites and time points during the
collection period.
A full blood count was performed from the 3-ml
EDTA blood sample using a Sysmex XN-2000 haematol-
ogy analyser (Sysmex UK Limited, Milton Keynes, UK)
to generate an extended profile of blood cell indices. Full
blood count results of all participants were reviewed by
the Haematology Review Group to identify clinically
significant results for further consideration. Following
centrifugation, the 6-ml EDTA sample was used to ex-
tract two 0.8-ml plasma aliquots and buffy coat, while
the 6-ml serum sample yields two 0.8-ml aliquots. The
plasma, serum and buffy coat aliquots are stored at
-80°C prior to planned use (such as for serum ferritin
analyses and DNA extraction from buffy coat). This
sample collection protocol is being repeated in all par-
ticipants at their last donation prior to completing
their 2-year involvement in the trial. If donors are de-
ferred or medically withdrawn from blood donation at
the time their final research sample is due, they are be-
ing offered an appointment to give a research sample.
Data collection between randomisation and the 2-year
assessment
Participants are requested via email to complete an online
questionnaire every 6 months during the trial follow-up
period. The follow-up questionnaires collect information
on the following:
1. Compulsory questions including month and year of
birth to validate completion of the questionnaire by
the individual to whom it is sent.
Table 3 (Serious) adverse events collected at 6-month
intervals after randomisation, including serious adverse
events, diagnoses and symptoms of low iron
Type of adverse event Description
Data collected at 6, 12, 18 and 24 months
Serious adverse events, diagnosed/
treated at hospital or by a doctor
Heart problems including heart
attack, stroke, mini-stroke, angina,
heart failure
Falls
Transport accidents (when in
charge of a vehicle)
New illness
Diagnoses of low iron Diagnosis of low haemoglobin by
NHSBT
Diagnosis of anaemia by general
practitioner (GP) or hospital
Prescription of iron supplements
Symptoms Tiredness
Dizziness
Feeling faint
Fainting
Fit or seizure
Breathlessness
Palpitations
Chest pain
Restless legs [22]
Additional data collected at 24 months
Symptoms Severity of breathlessness [23]
Severity of palpitations (that is,
resulted in ECG?)
Severity of chest pain (that is,
resulted in ECG?)
Headaches
Sleep disturbances
Irritability
Reduced ability to concentrate
Restlessness/inability to relax
Pica
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version of the SF-36v2 was chosen to reduce time
burden on participants [21], as it takes only 5 minutes
to complete. We are using information from this
questionnaire to monitor participants’ self-rated health
during the trial and provide a means to assess potential
bias of trial outcomes due to selective attrition.
3. (Serious) adverse events ((S)AEs), which are assessed
to monitor donor safety throughout their 2-year
participation in the trial. Questions on (S)AEs are
designed to take about 5 minutes to complete and
include adverse events diagnosed/treated at hospital
or by a doctor, diagnoses of low iron and symptoms
associated iron deficiency (see Table 3).
Data collection at the 2-year assessment
On the anniversary of participants’ 2-year involvement
in the trial, an email request is sent to participants
requesting completion of a final 35-minute questionnaire
which collects information on the following:
1. Month and year of birth as well as sex in order to
validate the identity of the person completing the
questionnaire.
2. Quality of life using the SF-36v2 questionnaire.
3. (Serious) adverse events. At this time-point an enhanced
set of questions ask about a broader range of symptoms
and the severity of selected symptoms (see Table 3).
4. Medication and supplement use, including
glucose-lowering, antihypertensive, and lipid-lowering
drugs as well as use of over-the-counter dietary or
vitamin supplements (with a specific additional
question on whether these supplements contain iron).
5. Cognitive function tests, including Stroop Test
(attention and reaction times), Trail Making Test
(executive function), Pairs Test (Episodic Memory),
and Reasoning Tests (intelligence). These tests,
which have been adapted from the Cardiff Cognitive
Battery, have been specifically designed for cognitive
testing in epidemiological settings [24]. The tests
are preceded by a five-item mood questionnaire to
adjust for effects that may skew results of cognitive
function [25,26].
6. Donor beliefs and ideas about blood donation, and
in particular whether increased frequency of
donation raises specific difficulties or concerns; these
questionnaire data will be augmented by a small
number of in-depth interviews.
7. Invitation to take part in physical activity
monitoring.
8. Recent physical activity questionnaire (RPAQ) which
includes questions about physical activity during the
past 4 weeks across four domains (leisure time,
occupation, commuting and domestic life) [27,28].The administration and reminder procedures for the
baseline, interim, and final questionnaires have been
identical.Physical activity monitoring
As part of the 2-year assessment, all participants will be
invited to take part in physical activity monitoring using
the tri-axial accelerometer AX3 (Axivity, York, UK) to
measure the impact of more frequent blood donations
on activity levels. Donors who respond positively will be
randomly selected to take part, with a target of 1,000
Table 4 Pre-specified subgroups with suspected higher or
lower susceptibility to iron deficiency following blood
donation
Estimated prevalence in
National Health Service
Blood and Transplant donor
population
More resilient to deferral and iron deficiency
Men 47%
Carriers of the human
haemochromatosis (HFE)
gene variants
(C282Y and H63D)
27%
Women aged >50 y 20%
Serum ferritin levels
above 95th percentile
5%
Less resilient to iron deficiency
Body mass index <22 kg/m2 14%
New blood donors 10%
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intervention groups.
Cost effectiveness analysis
A full economic analysis of alternative strategies for
maintaining the supply of blood to the NHS is planned.
INTERVAL trial data will be used to estimate the effect
of reduced minimum inter-donation intervals on the
number of blood donations made, donor’s quality of life,
deferral and costs. A discrete event simulation model
will be developed to extrapolate the cost effectiveness of
alternative minimum donation intervals over 10 years.
Data from NHSBT’s donor register (the PULSE database,
Savant, Burton-in-Kendal, UK) will be accessed to
provide donor characteristics and donation history to
define the target population, and to estimate long-term
rates of donation, under current minimum recall inter-
vals, and characteristics of the blood collection service.
Discrete choice experiments will be conducted to investi-
gate donor willingness to donate blood under future
changes to the blood collection service. The analysis will
use the findings from the discrete choice experiments,
together with those from the re-analyses of INTERVAL
and PULSE data, to estimate the cost-effectiveness of
alternative blood collection strategies over a 10-year time
horizon for general populations of whole blood donors.
Outcome measures
Primary outcome
The primary outcome is the number of blood donations
made over 2 years. The number of blood donations up to
(and not including) the 2-year anniversary date of recruit-
ment will be counted.
Key secondary outcome
The key secondary outcome is physical well-being at
2 years, derived from the PCS of the SF-36v2 [21].
Other secondary outcomes
Other secondary outcomes, also to be assessed at 2 years,
will include the following:
i) The number of ‘deferrals’ of donors over the 2 years
of the trial due to low haemoglobin levels and/or
other factors (for example, clinical reasons, tattoos,
piercings, and foreign travel).
ii) Measures of iron status, including serum ferritin and
reticulocyte haemoglobin.
iii)Cognitive function tests of attention, executive
function, intelligence, and episodic memory.
iv) Physical activity measured by accelerometry.
v) Cost effectiveness.
vi) Donor attitudes assessed through questionnaire
responses and interviews.Sample size
General considerations
The trial’s sample size was determined on the basis of
partially overlapping considerations, including NHSBT's
duty of care to 1.4 million blood donors per year (mak-
ing it vital for the service to ascertain even subtle
changes in health and well-being related to blood dona-
tion) and the need to generate sufficiently compelling
evidence to influence regulators and policy-makers,
since substantial benefits to the blood supply (and value
for money for NHSBT) could accrue with even a com-
paratively small, but definite, increase in blood donation
rates. As noted above, we have pre-specified interest in
several subgroups because they seem a priori either
more or less able to give blood on a more frequent basis.
These donor groups are summarised in Table 4 together
with their estimated prevalence based on data from pre-
vious studies [13,29-31]. Furthermore, we will identify
people in the top 20% for hereditary ‘robustness’ in rela-
tion to iron homeostasis/red cell indices by using genetic
risk scores that summarise many genetic variants rele-
vant to these traits.
Sample size calculations related to the outcomes
This trial has been powered on its primary endpoint
(number of blood donations over 2 years) and key sec-
ondary endpoint (physical component quality of life
score).
(1) Number of blood donations: As the men in this trial
are assigned to 12-wk versus 10-wk versus 8-wk inter-
donation intervals, the maximum number of donations
possible over the 2-year trial duration are 8, 10, and 12
donations, respectively (that is, a 25% proportional in-
crease in donation rates when comparing a 10-wk versus
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comparing a 8-wk versus 12-wk frequency). Women are
assigned to 16-wk versus 14-wk versus 12-wk inter-
donation intervals, corresponding to a maximum number
of donations over 2 years of 6, 7, and 8 respectively.
However, when considering the current nonattendance
rates of donors, such maximal differences based on
more frequent donation intervals are unlikely to be
achieved in practice.0
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tion rate = 1.6 times/yr in the standard donation fre-
quency group (control), and between subject SD = 0.7
times/yr in each group.
(2) Quality of life: After making allowances for up to
one third of participants not completing the final ques-
tionnaire, Figure 2b shows that 50,000 trial participants
will provide 80% power to detect ≥3% mean difference
in the PCS of the SF-36 in subgroups with a prevalence
of ≥10%. This assumes a type I error = 0.05 and PCS = 50
in the standard donation frequency group (control), and
between subject SD = 10 in each group. As a comparative
benchmark, Patterson [32] showed a 3% (1.5-point) differ-
ence in the SF-36 PCS in women who self-reported iron
deficiency in the past two years compared with those who
had no such history.
Data analysis
Principles
Intention-to-treat analyses will be used, comparing groups
as randomised. Results for men and women will be analysed
separately. The principal pair-wise comparisons of groups
for men will be between 10-wk and 12-wk, and be-
tween 8-wk and 12-wk intervals. For women, these com-
parisons will be between 14-wk and 16-wk, and between
12-wk and 16-wk intervals. For outcomes assessed at both
baseline and at the 2-year follow-up, analyses of the 2-year
follow-up measures will be adjusted for the baseline mea-
sures. Other baseline characteristics (age, centre, BMI and
weight, SF-36v2 physical and mental component scores,
haemoglobin and ferritin) will be adjusted for in secondary
analyses. Tests of interaction will assess whether results
differ between the subgroups pre-specified above. Multiple
testing will be taken into account when interpreting these
results. The trial will be reported according to CONSORT
guidelines.
End-of-trial analyses
The total blood collected by 2 years will be expressed in
units (470 ml) per person per year. Means will be compared
between groups using a t-test, with subsidiary analyses of
covariance adjusting for baseline characteristics. The mean
differences between groups in the PCS of the SF-36v2 will
be adjusted for baseline PCS by analysis of covariance, and
in secondary analyses for other baseline characteristics. Pos-
sible bias from missing data will be investigated by multiple
imputation within each randomised group based on sequen-
tial additions to the imputation model: (1) baseline charac-
teristics, (2) interim SF-12v2 scores, (3) deferral at previous
blood collections, (4) number of blood collections made,
and (5) number of reminders to elicit web questionnaire
responses [33-35]. Other secondary outcomes will be
analysed similarly. The proportion of deferrals will be ana-
lysed using logistic regression, allowing for potential over-dispersion between individuals. The baseline predictors
(including genetic characteristics) of levels of haemoglobin
and ferritin, and rates of deferral will be investigated using
multiple (logistic) regression, employing cross-validation
techniques to prevent over-fitting [36].
Ethical and safety issues
The trial has received ethics committee approval from
the National Research Ethics Service Committee East of
England - Cambridge East (Research Ethics Committee
(REC) reference 11/EE/0538). It is important to note
that the features used to ensure the safety of donors in
routine blood donation in NHSBT are being used to
ensure the safety of donors in the INTERVAL trial.
The role of the trial’s Independent Data Monitoring
Committee is to provide independent advice, based on
un-blinded analysis of data, to the Trial Steering Com-
mittee in order to ensure the safety of the participants.
Hence, at least every 6 months, the trial’s Independent
Data Monitoring Committee reviews un-blinded safety
data provided by the trial’s independent statistician.
These results derive from the various sources described
above, including the SF-12v2 questionnaire data and the
self-reported adverse events questionnaire.
An increase in deferrals or adverse events compared
to habitual donation patterns may prompt participants
to request withdrawal from the trial. Participants are free
to withdraw from the trial at any time without giving
reasons. However, in order to maintain maximal data
capture participants are asked to continue to complete
the trial questionnaires without donating blood. If
participants still wish to withdraw from the trial, then
they are given the option to allow permission to the re-
search team to retain and use data already collected from
them. Participants are free to opt out of this permission.
Patient and public involvement
Donors have been involved in the design and under-
taking of the INTERVAL trial in several ways, such as
through (1) provision of feedback during the pilot study
preceding this trial (that is, the Cambridge Cardio-
Resource Study) via questionnaires, interviews, and
helpline services; (2) review of research proposals and
questionnaires; and (3) membership on the Trial Steering
Committee.
Trial oversight
In addition to the Independent Data Monitoring Com-
mittee and the Research Ethics Committee mentioned
above, INTERVAL benefits from the input of other trial
oversight committees. The Trial Steering Committee
(which includes several senior clinical and academic
members who are independent from the trial investiga-
tors, a lay representative, and representatives of various
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duct of the trial and, through its independent Chair,
provides strategic advice to the Trial Management
Group. The Trial Management Group (which includes
the investigators, trial coordinators, and operational staff
from NHSBT) is responsible for overseeing day-to-day
management of the study, liaising with NHSBT, and
agreeing protocol amendments prior to submission to
the research ethics committee.
Discussion
To our knowledge, there are no previous or planned
randomised trials in the UK or elsewhere that aim to
define optimum inter-donation intervals and/or tailor
such intervals to particular groups of blood donors.
Although some randomised trials have been conducted
or are in progress to evaluate the impact of oral iron
supplementation [37,38], they are complementary to
INTERVAL and evaluate populations outside the UK.
The INTERVAL randomised trial is also complemen-
tary to recent major observational studies reported in
blood donors, such as those in the US [39] and in con-
tinental Europe [40].
In summary, the experience so far of the INTERVAL
trial suggests that it is possible to embed large-scale
clinical research within NHSBT without disruption to
routine services, and in a manner that is acceptable to
donors. The INTERVAL trial will yield novel informa-
tion about the effect of inter-donation intervals on
donors’ physical and mental well-being as well as on
blood services. The study will generate scientific evi-
dence to help formulate blood collection policies in
England and elsewhere.
Trial status
Recruitment in INTERVAL was completed on 15 June 2014.
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